AbbVie与西利奥合作开发有针对性的癌症免疫疗法,前期投资52M。 AbbVie partners with Xilio to develop targeted cancer immunotherapies, investing $52M upfront.

AbbVie和Xilio治疗机构合作开发了新的癌症治疗方法,重点是肿瘤活性免疫疗法。 AbbVie and Xilio Therapeutics have partnered to develop new cancer treatments, focusing on tumor-activated immunotherapies. Xilio 将获得 5200 万美元的预付款，其中包括 1000 万美元的投资，并可能额外获得高达 21 亿美元的里程碑付款。 Xilio will receive $52 million upfront, including a $10 million investment, and could earn up to $2.1 billion more in milestone payments. 合作利用Xilio的肿瘤激活技术来创造下一代免疫疗法,包括T细胞注射器。 T细胞注射器旨在通过只在肿瘤中激活来提高安全性和有效性。 The collaboration leverages Xilio's tumor-activation technology to create next-generation immunotherapies, including T-cell engagers, which are designed to improve safety and effectiveness by activating only in tumors.